health canada says it has received 15 requests for the use of psilocybin or mdma — a psychedelic drug with stimulant properties — since resuming the program.
in april, a clinic called roots to thrive, in nanaimo, b.c., became the first health centre in canada to offer a legal psilocybin group therapy program, in which hartle took part.
“the therapy part has a capital t in this whole process,” hartle said. “it isn’t just taking psychedelics. it’s just a tool in the process; the therapy is crucial to getting a good outcome.”
psychedelic-assisted treatment, bui-nguyen explained, requires multiple therapy sessions before and after patients experience the drug. patients will consume psilocybin while they are supervised by two psychotherapists and remain in the clinic-secured environment for up to six hours.
“it’s not miraculous,” bui-nguyen said. “you don’t take psilocybin and that’s it, a psychedelic trip and after the depression is cured — no! the patient has a lot of work to do. but it opens perspectives; it creates new paths in the brain that we aren’t used to taking. the patient then explores new roads to get out of depression.”
in the world’s largest study on psychedelics’ affect on the brain, released in march in the journal science advances, lead author danilo bzdok said psychedelic drugs might just be the next big thing to improve clinical care of major mental health conditions.